Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
ADNOC Gas Targets Up to $4B Profit in 2026 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
PARSIPPANY, N.J., Feb. 22, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2017 financial results before the open of the U.S. markets on Wednesday February 28, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 5198726. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 5198726. The replay of the call will be available for one week from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
